This company is engaged in developing and commercialising high_- quality biosimilars, which are cost - effective alternatives to branded biologic CRIMINAL_CHARGE. It_started_its operations in DATE DATE. The registered_business office of the company is strategically_located in CITY,_COUNTRY. The company specialises in developing and commercialising a range of biosimilars, including recombinant_human insulin, insulin analogues (glargine and aspart), monoclonal_antibodies (bTrastuzumab, bBevacizumab, bPegfilgrastim, bAdalimumab), and conjugated recombinant proteins (bEtanercept), with a focus_on CAUSE_OF_DEATH,_CAUSE_OF_DEATH, autoimmune CAUSE_OF_DEATH, and other serious conditions. It is a leading global_player in the biosimilars industry in COUNTRY. The company aims_to transform patient outcomes by making life - changing therapies more accessible and affordable globally. The company 's_vision is to_be a global TITLE in biologics, delivering_innovative and inclusive healthcare solutions. It is the ORDINAL company globally to receive ORGANIZATION ORGANIZATION approval for biosimilars such_as bTrastuzumab (DATE), bPegfilgrastim (DATE), and interchangeable bGlargine (DATE). The company has strategic alliances, such_as the NUMBER with ORGANIZATION ORGANIZATION ORGANIZATION ORGANIZATION.